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Abstract
Purpose In this prospective multi-centre observational
cohort study, we investigated the effect of an intensified
multidisciplinary pharmaceutical care programme on the
adherence of cancer patients treated with capecitabine, a
prodrug of fluorouracil.
Patients and methods Twenty-four colorectal and 24
breast cancer patients participated in this study. Patients
of the control group (n=24) received standard care,
patients of the intervention group (n=24) received
intensified pharmaceutical care consisting of written and
spoken information. Adherence to capecitabine chemo-
therapy was measured using an electronic medication
event monitoring system (MEMS™).
Results Patients in the intervention group exhibited an
enhanced but not significantly different mean overall
adherence compared to the control group (97.9% vs 90.5%,
p=0.069). Mean daily adherence was significantly higher in
the intervention group (96.8% vs 87.2%, p=0.029).
Variability of both adherence parameters was considerably
reduced when pharmaceutical care was provided. At the end
of the observation period of 126 days, the probability of still
being treated with capecitabine was found to be 48% in the
control group and 83% in the intervention group (p=0.019,
log-rank test). The relative risk for a deviating drug intake
interval, i.e. <10 or >14 instead of 12 h, in the intervention
group was found to be 0.51 (95% CI, 0.46–0.56) compared
with the control group (p<0.05, Chi-square test).
Relevance of the manuscript Efficacy of an orally administered
anticancer therapy depends on a high level of patient adherence. There
is still a lack of strategies to assure patient adherence in this particular
group of patients. This study presents a systematic and detailed
analysis on patient adherence to capecitabine chemotherapy. For the
first time, the impact of an intensified pharmaceutical care provision
on the adherence of patients receiving oral chemotherapy has been
studied.
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Introduction
Over the past decade, oral administration of anticancer agents
has gained increasing importance. Venepuncture and the risk
of extravasation are avoided, and oral administration allows
greater autonomy because patients can take their drugs
wherever they like. Capecitabine, cyclophosphamide, metho-
trexate, temozolomide and the so called ‘targeted drugs’ such
asimatinib,lapatinib,sorafenibandsunitinibareexamplesout
of a long list of oral anticancer agents. Despite these
advantages, oral administration is also accompanied by many
challenges. The potential toxicity of anticancer agents, the
recognition of adverse effects by the patient, the management
of adverse effects and the importance of patient's adherence
for treatment success are important issues that have to be
addressed. Multidisciplinary patient care and a good patient
education play a key role in a successful oral anticancer
treatment [1–-4].
In this study, we focused on patients receiving chemo-
therapy with capecitabine, a prodrug of fluorouracil (5 FU)
which is frequently used for the treatment of breast,
colorectal and gastric cancer patients [5]. One capecitabine
chemotherapy cycle consists of 2 weeks of twice daily drug
intake followed by 7 days of break. Since it is an orally
administered drug, patients take it usually at home. As for
all oral anticancer agents, a high adherence to the
prescribed dosage regimen is a major prerequisite for
therapeutic efficacy.
Adherence to prescribed medication has been in the
centre of interest in many chronic diseases. Several working
groups have focussed on adherence to antihypertensive
therapy or therapy of chronic heart failure and developed
strategies for enhancing adherence [6–10]. Others have
studied adherence in the elderly and patients with mental
disorders [11, 12]. So far, there are only few data available
which focus on adherence in cancer patients treated with an
oral anticancer drug as summarised in a recent review [13].
Most data are available for tamoxifen. Waterhouse et al.
used patient self-report, pill counts and microelectronic
monitoring (Medication Event Monitoring System
(MEMS)™) in 24 breast cancer patients to assess the
adherence to oral tamoxifen. Adherence rates differed
depending on the strategy of measurement: self-report
resulted in an overall adherence of 98.6±2.2%, pill counts
of 92.1±9.8% and microelectronic monitoring showed the
lowest rate with 85.4±17.2% [14]. Recently published
results on the persistence to tamoxifen therapy in 462 breast
cancer patients over 5 years revealed that 31% of patients
who started tamoxifen failed to complete the recommended
5-year course [15]. Lebovits et al. concentrated on
adherence to cyclophosphamide and prednisolone in 51
breast cancer patients, also assessed by patient self-report.
Non-adherence was defined as ingesting 90% or less of the
total prescribed dosage during 6 months of treatment.
Criteria for non-adherence were met by 43% of the patients
[16]. Adherence to oral etoposide measured in 12 patients
with small cell lung cancer by using an electronically
monitored tablet bottle adherence was reported to be 93.2±
12.0% [17].
First data on adherence to capecitabine using MEMS™
have recently been published. Only 76% of elderly breast
cancer patients took 80% or more of the prescribed doses
[18]. In contrast, in a younger breast cancer population
median adherence was found to be 96% [19].
Although in general, adherence to oral anticancer therapy
seems to be higher compared with other diseases, most of
these studies have shown that there is always a certain
number of cancer patients who might need specific inter-
ventions to assure adherence. In this study, we assessed the
adherence of breast and colorectal cancer patients treated
with capecitabine and the impact of a pharmaceutical care
intervention on patient adherence. Patient education by
pharmacists can improve patient outcome and adherence to
oral drugs as shown in a Cochrane review for other diseases
than cancer [20]. For oral chemotherapy, pharmacy services
are probably underused even in cancer centres [5]. The
pharmaceutical care intervention in this study was provided
by a team of two registered pharmacists with extensive
experience in this field and consisted of a combination of
written and spoken information. Adherence was assessed by
MEMS™ as this system provides precise and detailed
information about patients' behaviour in taking their medi-
cation including dose timing and drug holidays. However, it
does not prove that the patient really ingested the drug or
took the correct number of pills. This indirect approach,
however, currently provides the most reliable data on
adherence [21].
Methods
Study design
The study was conducted as a prospective, multi-centred
observational cohort study with control group. The control
group receiving standard care was studied before the
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ical care. As the latter must be regarded as a complex
intervention, some limitations with regard to the study
design had to be accepted [22]. A non-randomized design
was chosen for two reasons: Firstly, possible interactions
between patients of the two study groups could have led to
an undesired contamination with regard to the evaluation of
adherence in the control group. Secondly, learning effects
of participating physicians and nursing staff had to be
avoided with regard to the pharmaceutical care intervention.
Patient recruitment and study population
The study was approved by the ethics committee of the
University of Bonn, Germany. Patients were consecutively
recruited at three hospital sites (two departments of
internal medicine and one department of obstetrics and
gynaecology) and three ambulatory oncology practices.
The main inclusion criterion was that the patient started a
chemotherapy regimen with capecitabine as a single agent
or in combination with other agents for treatment of
colorectal or breast cancer. Patients had to be included into
the study within 2 weeks after the beginning of capecita-
bine therapy. The minimum age was defined as 18 years;
patients had to be able to speak and read German language
fluently and had to give written consent to participate.
Exclusion criteria were any prior orally administrable
chemotherapy and any disease compromising the patient
to fully understand the purpose and course of the study
(for example, Alzheimer's disease).
If an eligible patient was identified by one of the
collaborating oncologists, the patient was contacted within
24 h to organize a first meeting to provide the patient with
spoken and written information about the study. Patients
were given at least 24 h to decide whether they would want
to participate.
Sixty-nine ambulatory cancer patients were reported to the
pharmaceutical care team by the participating oncologists.
Fifty of those patients were included into the study, and data
were evaluated. Of 19 patients not included, three patients did
not give their consent to participate in the study and 11
patients did not meet at least one of the inclusion criteria. In
five cases, other reasons prevented the inclusion into the
study. One patient in each study group died during the
observation time and the MEMS™ vials were not returned.
Figure 1 provides an overview of the timeline of patient
inclusion into the control and intervention group.
Pharmaceutical care intervention
The intensified pharmaceutical care service for patients of
the intervention group consisted of a combination of written
and spoken information provided by two registered
pharmacists of the department of clinical pharmacy at the
University of Bonn, Germany. The initial patient consulta-
tion included the general information about the study, the
introduction to the study material and the course of the
study. Upon inclusion into the study, the characteristics of
the drug capecitabine, including mechanism of action,
possible adverse events and their appropriate management,
as well as the individual treatment regimen were explained
in detail. Furthermore, patients were informed about the
importance of a high adherence to this drug and the risks of
inadequate compliant behaviour. Patients were also edu-
cated about any other additional medication they were
taking. After conducting an interaction check and a change
in medication in cooperation with the physician where
necessary, patients were given a written dosing schedule by
the pharmaceutical care team. This dosing schedule
contained all current medications and special advice
regarding the drug administration where necessary and
was updated each cycle. Patients received a leaflet with
information about the prevention and management of
adverse effects of chemotherapy. They were contacted at
least once during each cycle of capecitabine chemotherapy
to inquire about any current therapy-related questions or
problems and to reconfirm the ongoing individual ther-
apeutic regimen. Issues discussed during these telephone
consultations ranged from management of adverse effects,
administration of chemotherapy and supportive therapy to
questions regarding additional complementary treatment
options. In some cases, the follow-up consultations took
place on the hospital or oncology practice site.
The median time required for the initial patient consulta-
tion (including general information about the study etc.) was
75.0 min. During the following course of the study, a median
of 2.2 consultations per cycle were held. The median
duration of these consultations was 6.0 min.
Adherence measurement
Patients received an activated MEMS™ vial and were
asked to use it to store their capecitabine medication for the
duration of their participation in the study. As demanded by
the responsible ethics committee for this study, they were
informed that the lid of the vial contained a micro-chip that
registered every opening of the container. They were
instructed to take medication only from the container and
not to open it for other reasons. Depending on the
prescribed dosing regimen of capecitabine therapy (dosing
in the observed patients ranged from two tablets twice daily
to four tablets twice daily), the MEMS™ vial had to be
refilled by the patient several times in the course of the
study. Patients were therefore asked to schedule refills of
the bottle at the same time as they were extracting tablets
for regular drug intake to avoid extra openings.
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note any extraordinary opening of the vial. Openings noted
by patients in this way were included into the adherence
analysis. After completion of six cycles of capecitabine
therapy or upon notification of an earlier stop of treatment
through the participating oncologists, the MEMS™
containers were collected from patients.
Adherence and persistence analysis
Adherence of patients of both study groups was analysed
using the data uploaded from the MEMS™ vials and
patients' notes regarding extraordinary openings.
Overall adherence was calculated by dividing the
number of actual openings recorded by the MEMS™
system by the number of expected openings. In addition,
daily adherence was calculated by dividing the number of
days with a correct number of openings of the MEMS™
vial by the number of days monitored. In the case of
capecitabine therapy in this study, a day with a correct
number of openings could either be a day with two
openings (during the 2 weeks of therapy) or with no
opening (during the 7 days of break). Therapy days with
less or more than two openings or days with any number of
openings during the scheduled therapy-free interval were
counted as non-adherent days.
Furthermore, adherence data were evaluated with regard
to persistence with therapy. For this purpose, duration of
capecitabine treatment was compared between both study
groups. Preplanned treatment discontinuations according to
the respective regimen and those due to death of patients
were censored.
Assessed for eligibility (n = 41)
Excluded (n = 16)
Not meeting inclusion criteria (n = 8)
Refused to participate (n = 3)
Other reasons (n = 5)
Analysed (n = 24)
Lost to follow-up (n = 1)
Reason: died during study and 
MEMSTM vial not returned
Allocated to control group (n = 25)
Received standard care (n = 25)
Analysis
Follow-Up
Enrollment
Control Group: First patient in 05/2006, Last patient in 10/2006, Last patient out 01/2007
Assessed for eligibility (n = 28)
Excluded (n = 3)
Not meeting inclusion criteria (n = 3)
Analysed (n = 24)
Lost to follow-up (n = 1)
Reason: died during study and 
MEMSTM vial not returned
Allocated to intervention group (n = 25)
Received intensified pharmaceutical
care (n = 25)
Analysis
Follow-Up
Enrollment
Intervention Group: First patient in 12/2006, Last patient in 07/2007, Last patient out 10/2007
Fig. 1 Flow diagram of patient
recruitment
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between two openings of the MEMS™ container. Intervals
≥24 h were excluded from this analysis. Intervals of 12±2 h
were defined as adherent. Relative risk was calculated for
intervals outside this timeframe. Also, the ‘number needed to
treat’ was calculated to prevent one non-adherent interval by
the pharmaceutical care intervention.
Sample size calculation and statistical analysis
Daily adherence was selected as primary endpoint of this
study; the other measured parameters were regarded as
secondary endpoints. Since no prior data on daily
adherence to capecitabine were available, we assumed a
daily adherence of 79.1% for the control group according
to a published meta-analysis [23]. Target daily adherence
for the intervention group was 95%. Assuming an alpha
error of 5% and an intra-patient correlation of 0.25
(estimated from the Pharmionic Knowledge Center data-
base, Pharmionic Systems, Sion, Switzerland) resulted in a
sample size of 17 patients for each study group (power of
80%). Considering a potential drop-out rate of 25% led to
a final sample size of 22 patients for each group.
The statistical analysis in this study was performed using
SPSS™ for Windows, Version 15.0 (SPSS Inc., USA) and
Microsoft™ Excel 2000 (Microsoft Corporation, USA).
The non-parametric Mann–Whitney U test was used to
compare adherence parameters in both patient groups.
Duration of capecitabine treatment was compared by
performing a Kaplan–Meier survival analysis and the log-
rank test. Influence of the intervention on regularity of intake
intervals was evaluated by 95% confidence intervals and the
Chi-square test. The level of significance was set to p<0.05.
Results
Patient characteristics
Adherence was assessed in 24 breast and 24 colorectal
cancer patients. There was no statistically significant
difference between the control and the intervention group
with regard to age, gender and number of additional oral
medications in use at the time of inclusion into the study.
With regard to gender (p=0.002, Mann–Whitney U test)
and age (p=0.001, Mann–Whitney U test), there was a
statistically significant difference between the two diag-
nosis groups (breast and colorectal cancer) regardless of
the study group affiliation. Table 1 summarises demo-
graphic characteristics of the study population and
provides an overview of the observation period, the
number of completed capecitabine cycles and the number
of additional medications.
Adherence analysis
The observation period in the control group ranged from 13
to 128 days and in the intervention group from 9 to
138 days. Tables 2 and 3 show the adherence results for
each patient over the observation period expressed in
overall and daily adherence. The intervention group showed
an increased but not significantly different mean overall
adherence of 97.9% (Median=99.0%, p=0.069, Mann–
Whitney U test) compared with a mean overall adherence
of 90.5% in the control group (Median=96.2%). Mean
daily adherence was significantly (p=0.029) improved from
87.2% in the control group (Median=93.8%) to 96.8% in
the intervention group (Median=98.5%). Figures 2 and 3
illustrate the differences in overall and daily adherence
between the two study groups. Moreover, the intervention
led to a decrease of variability with regard to the adherence
parameters in the intervention group.
Table 4 presents an overview of the total and relative
number of patients in both groups with adherence parameters
below 90% and 80%. These adherence limits had been
defined in the study protocol on the basis of empirical
considerations. None of the patients having received the
pharmaceutical care intervention showed an overall or daily
adherence below 80%; whereas in the control group, five
(21%) patients showed an overall and six (25%) a daily
adherence below 80%.
Duration of capecitabine treatment and persistence
Figure 4 illustrates the comparison of the time period
patients were kept on capecitabine chemotherapy between
the control and intervention group. At the end of the
observation period of 126 days the probability of still being
treated with capecitabine in the control group was found to
be 48% and in the intervention group 83%. This difference
was statistically significant (p=0.019, log-rank test).
The data of two control patients (B12 and C08) were
censored because their treatment stop was due to their neo-
adjuvant chemotherapy regimens and neither due to toxicity
nor tumour progress. Ten of 12 treatment aborts in the
control group were linked to serious adverse events (nine)
and non-response to chemotherapy associated with disease
progression (one). One patient stopped his therapy arbitra-
rily due to lack of motivation and in one case the reason for
treatment disruption remained unknown.
In the intervention group, data of three patients were
censored. In one case, therapy was stopped due to the
death of the patient (BI05) and in two other cases it was
stopped according to the originally scheduled treatment
plan (CI05 and CI11). The four treatment aborts in this
group were linked to adverse events (two) and disease
progression (two).
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noteworthy problems with regard to arbitrary non-
persistence. Only three patients of the control group
stopped taking their capecitabine chemotherapy without
prior consent of their oncologist. In all three cases the
oncologist approved this treatment interruption a few days
later and chemotherapy prescription with capecitabine was
ultimately stopped.
Drug intake intervals
Table 5 shows the 2×2 table used to calculate the relative risk
to exhibit an irregular intake interval, i.e. outside the defined
borders (>14 or <10 h). The relative risk for the intervention
group was 0.51 (confidence interval, 95% 0.46–0.56). The
Chi-square test indicated that the difference was significant
(p<0.05, one degree of freedom). Additionally, the ‘number
needed to treat’ was calculated to prevent one non-adherent
intake interval. By calculation of the reciprocal of the
absolute risk reduction the number needed to treat was
found to be 5.7, i.e. six intake intervals need to be supported
by the evaluated pharmaceutical care intervention in order to
prevent one interval >14 or <10 h.
Discussion
Our study revealed the potential of adherence enhancement
by providing intensified pharmaceutical care. However, a
number of limitations have to be considered before
interpreting the data. Apart from the relatively small
number of patients, we chose a non-randomized study
design due to the fact that pharmaceutical care must be
regarded as a highly complex intervention [22]. A parallel
design could have led to significant contamination bias
because of the interaction that occurs between clinic
patients. In addition, since blinding is not possible with
this intervention, healthcare professionals might have
adopted an approach to patient follow-up counseling that
was dependent upon the intervention received. Therefore,
Sociodemographic characteristics Control group (n=24) Intervention group (n=24)
Mean (SD) age (years)
Breast cancer 57.5 (11.6) 55.9 (11.0)
Colorectal cancer 69.8 (9.4) 66.0 (12.0)
Sex
Female 18 19
Male 6 5
Diagnosis
Breast cancer 12 12
Colorectal cancer 12 12
Chemotherapy regimen at time of inclusion
Cap (monotherapy) 11 12
Cap Vin 3 0
Cap EC 1 0
Cap Pac 1 2
Cap Beva 3 2
Cap Ox 3 4
Cap Beva Ox 2 0
Cap Beva Iri 0 1
Cap Iri Cet 0 1
Cap Lap 0 2
Median (range) no. of additional medications
a
Breast cancer 4 (1–10) 5 (2–15)
Colorectal cancer 3.5 (0–8) 7 (1–13)
Median (range) days monitored
Breast cancer 64 (13–119) 104 (9–119)
Colorectal cancer 73 (21–128) 118 (31–138)
Median (range) number of completed cycles
Breast cancer 2.5 (0–6) 4.0 (0–6)
Colorectal cancer 2.5 (1–6) 4.0 (1–5)
Table 1 Demographic
characteristics
Cap capecitabine, Vin vinorel-
bine, EC epirubicin+cyclophos-
phamide, Pac paclitaxel, Beva
bevacizumab, Ox oxaliplatin, Iri
irinotecan, Cet cetuximab, Lap
lapatinib
aAt time of inclusion
1014 Support Care Cancer (2011) 19:1009–1018we decided to recruit first the control group and sub-
sequently the intervention group in each participating
centre.
The basis for the evaluation of adherence in this study
were the two parameters overall and daily adherence as
proposed by Vrijens and Goetghebeur [24]. It is remarkable
that median overall adherence of 96% in our control group
was the same as that reported by Mayer et al. for 13
metastatic breast cancer patients using the same method
[19]. Median daily adherence of 94% was found to be a bit
lower compared with overall adherence in the control
group. Even if taking into account that MEMS™ results
can be biased by an altered behaviour of the patients being
aware of the observation (‘Hawthorne effect’), one may
conclude that adherence does not represent a major problem
in this patient population. A closer look into the data,
however, shows that there are individual patients with
relatively low adherence. Two of our patients in the control
group took only 50% or less of their prescribed doses
which may most likely endanger therapeutic efficacy. Six
(25.0%) patients in the control group did not take their
medication as prescribed on at least every fifth day. In the
study of Muss et al. in elderly patients, only 76% exhibited
an overall adherence to capecitabine of 80% or higher [18].
These results indicate that there are subgroups of patients
with low adherence that might benefit from adherence-
enhancing measures. From a health professional’s perspec-
tive it must be desirable to identify such patients as early as
possible in order to initiate adherence-enhancing activities.
Using the data of electronic monitoring devices during
routine patient consultations could be one way to ensure
early detection of potential non-compliers and discuss
adherence-enhancing measures with the patient [25].
The pharmaceutical care intervention led to an improve-
ment of both overall and daily adherence although only the
difference in daily adherence was significantly different. The
intervention resulted in a decrease of variability with regard
to all assessed adherence parameters. This outcome of the
Table 2 Adherence data of the control group
Patient No of openings
(expected)
No of openings
(actual)
Overall adherence
(%)
Days with correct drug
intake
Days
monitored
Daily adherence
(%)
B 01 31 29 93.5 21.5 23.0 93.5
B 02 27 17 63.0 13.5 21.0 64.3
B 03 148 142 95.9 108.0 116.0 93.1
B 04 11 11 100.0 13.0 14.0 92.9
B 05 166 161 97.0 113.0 118.0 95.8
B 06 168 167 99.4 118.0 119.0 99.2
B 07 73 70 95.9 48.0 51.0 94.1
B 08 166 166 100.0 118.0 118.0 100.0
B 09 108 128 118.5 67.0 92.0 72.8
B 10 71 71 100.0 56.5 56.5 100.0
B 11 26 26 100.0 13.0 13.0 100.0
B 12 100 95 95.0 66.0 71.0 93.0
C 01 106 75 70.8 51.0 76.0 67.1
C 02 102 97 95.1 86.0 90.0 95.6
C 03 152 124 81.6 95.0 118.0 80.5
C 04 96 71 74.0 47.0 69.0 68.1
C 05 40 37 92.5 25.5 28.0 91.1
C 06 168 162 96.4 122.0 128.0 95.3
C 07 52 26 50.0 13.0 36.0 36.1
C 08 56 56 100.0 35.0 35.0 100.0
C 09 28 28 100.0 21.0 21.0 100.0
C 10 29 14 48.3 14.5 22.0 65.9
C 11 56 60 107.1 107.0 112.0 95.5
C 12 164 162 98.8 115.0 117.0 98.3
Mean 89.3 83.1 90.5 62.0 69.4 87.2
Median 84.5 71.0 96.2 53.8 70.0 93.8
Range 11–168 11–167 48.3–118.5 13.0–122.0 13.0–128.0 36.1–100.0
B breast cancer patient, C colorectal cancer patient
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Fig. 2 Boxplot of overall adherence in the control and intervention
group
Table 3 Adherence data of the intervention group
Patient No of openings
(expected)
No of openings
(actual)
Overall adherence
(%)
Days with correct drug
intake
Days
monitored
Daily adherence
(%)
B I01 165 165 100.0 117.5 117.5 100.0
B I02 165 159 96.4 112.5 117.5 95.7
B I03 163 166 101.8 111.5 116.5 95.7
B I04 136 136 100.0 96.0 96.0 100.0
B I05 31 29 93.5 21.0 22.5 93.3
B I06 124 126 101.6 109.0 111.0 98.2
B I07 20 21 105.0 9.5 10.5 90.5
B I08 163 163 100.0 116.5 116.5 100.0
B I09 112 113 100.9 76.0 77.0 98.7
B I10 18 15 83.3 8.5 9.0 94.4
B I11 18 17 94.4 8.0 9.0 88.9
B I12 168 168 100.0 119.0 119.0 100.0
C I01 112 109 97.3 112.0 119.0 94.1
C I02 111 114 102.7 135.5 137.5 98.5
C I03 138 138 100.0 117.0 118.0 99.2
C I04 155 151 97.4 111.5 112.0 99.6
C I05 111 109 98.2 75.5 76.5 98.7
C I06 165 166 100.6 116.5 117.5 99.1
C I07 160 155 96.9 125.5 128.5 97.7
C I08 131 130 99.2 114.0 115.0 99.1
C I09 167 165 98.8 118.5 118.5 100.0
C I10 51 45 88.2 28.5 33.0 86.4
C I11 45 43 95.6 30.0 30.5 98.4
C I12 145 141 97.2 122.0 125.0 97.6
Mean 115.6 114.3 97.9 88.0 89.7 96.8
Median 133.5 133.0 99.0 111.8 115.8 98.5
Range 18–168 15–168 83.3–105.0 8.0–135.5 9.0–137.5 86.4–100.0
B breast cancer patient, C colorectal cancer patient
1016 Support Care Cancer (2011) 19:1009–1018adherence-enhancing intervention is further documented by
the fact that none of the patients of the intervention group
showed an overall or daily adherence below 80%. As
limiting factor for the interpretation of our data it has to be
pointed out that the adherence limit of 80% is a purely
arbitrary cut-off which is not based upon any objective dose
response data. It would be desirable to define an adequate
adherence as result of dose efficacy studies which would
allow the assessment of results of adherence-enhancing
interventions with regard to their clinical significance. The
importance of demonstrating positive influence of clinically
relevantoutcomes hasbeen discussed byKripalanietal.who
concluded that only very few adherence studies fulfil this
demand [26].
When regarding the adherence parameters in this study,
some patients demonstrated an overall adherence above
100%. However, as a result of the analysis of the individual
MEMS™ adherence profiles it can be concluded that more
doses than prescribed were only taken in very few cases.
These patients reported that they took an additional dose
during the evening because they simply couldn’t remember
the earlier intake, which resulted in an overestimation of
overall adherence coupled with a decrease of daily
adherence. The studied population did not show the often
discussed phenomenon of over-adherence, i.e. that patients
are over-motivated and take more doses than prescribed by
the physician [27].
The significant effect of the pharmaceutical care
intervention on the duration of capecitabine chemotherapy
is noteworthy. In nine patients of the control group the
therapy was stopped due to the development of severe
toxicity, compared to only two patients in the intervention
group. This could be a consequence of the intensive
patient education during the pharmaceutical care consul-
tations. Patients who are well informed and know what to
expect during the course of therapy are better prepared
how to manage adverse effects and the development of a
therapy-limiting dimension of toxic symptoms is less
likely [28]. However, this observation may be due to
chance imbalances in this small population and requires
confirmation in a large randomized trial.
Last but not the least, the intervention also demonstrated
a significant effect on the regularity of drug intake intervals.
The ‘number needed to treat’ of six could allow the
interpretation that a pharmaceutical care programme for
patients receiving twice daily capecitabine would prevent
one non-adherent intake interval every three days. The
authors are aware that it is not clear yet which extent of
variability of the dosage interval is acceptable without
consequences for efficacy and toxicity. However, the result
underlines the potential of pharmaceutical care pro-
grammes. It is certainly worth developing such programmes
as a multidisciplinary approach to assure safe and effective
oral anticancer therapy.
Conclusions
The results of this study demonstrate the potential of
intensified pharmaceutical care provision to improve treat-
ment outcome of oral chemotherapy. The pharmaceutical care
intervention resulted in a significant improvement of patient
adherence. Moreover, patients receiving intensified pharma-
ceutical care were kept longer on their capecitabine regimen
and showed better regularity with regard to drug intake
intervals. The development of an adherence monitoring and
enhancing infrastructure is a necessary prerequisite to exploit
the full potential of orally administrable chemotherapies.
Fig. 4 Kaplan–Meier plot of treatment duration in the control (solid
line) and intervention group (dotted line)
Table 4 Number of non-adherent patients in both patient groups
Control group (n=24) Intervention group (n=24)
Overall adherence
<80% 5 (21%) 0
<90% 6 (25%) 2 (8%)
Daily adherence
<80% 6 (25%) 0
<90% 7 (28%) 2 (8%)
Table 5 A 2×2 table to calculate relative risk for intake intervals
outside defined borders
Intervals Intervals Total
<10h/>14h ≥10h/≤14h
Intervention group 480 2,187 2,667
Control group 676 1,221 1,897
Total 1,156 3,408 4,564
Support Care Cancer (2011) 19:1009–1018 1017Screening systems to detect potential non-adherers would
support the rational utilization of the required resources.
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